Compare TRDA & FPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | FPI |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 541.2M |
| IPO Year | 2021 | 2013 |
| Metric | TRDA | FPI |
|---|---|---|
| Price | $13.41 | $11.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 191.2K | ★ 418.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | $25,421,000.00 | ★ $52,178,000.00 |
| Revenue This Year | $39.97 | N/A |
| Revenue Next Year | $50.80 | N/A |
| P/E Ratio | ★ N/A | $18.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $9.37 |
| 52 Week High | $13.99 | $13.23 |
| Indicator | TRDA | FPI |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 42.08 |
| Support Level | $10.84 | $10.84 |
| Resistance Level | $13.99 | $11.65 |
| Average True Range (ATR) | 0.77 | 0.30 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 94.06 | 30.89 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.